anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ANAVEX3-71-SZ-001 is a two-part study. The first part is Part A: Multiple Ascending Dose, PK, safety, and dose selection. The second part is Part B: Double Blind, Placebo Controlled for exploratory efficacy and continued repeat-dose safety. This study will investigate the effects of ANAVEX3-71 in patients with Schizophrenia for the first time. This is an in-patient study. In both parts, participants will undergo either 10 or 28 days of dosing (Part A and Part B, respectively). Standard clinical outcome measures used in the clinic and novel fluid and electrophysiological biomarkers will also be assessed.
A composition comprising a powdered cellulose and a signalling agent is claimed. Preferably the signalling agent is mint, spearmint, eucalyptus, menthol or a combination thereof. The cellulose may be a methyl cellulose including hydroxypropylmethylcellulose. The composition is for nasal administration and may further be a powder. It may include a therapeutically active ingredient, such as an antibacterial, antifungal, antibiotic, anti-inflammatory, anti-insomnia agent, cognitive enhancer, cardiovascular agent or corticosteroid. The active ingredient may be allicin, aspirin, St John's wort, valerian extract, gingko biloba. The use of such compositions in therapy or prophylaxis is claimed, especially asthma or allergic rhinitis. Also claimed is the killing of Staphylococcus aureus. Kits for preparing the composition are also claimed.
Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
The invention provides a pantoprazole sodium composition for injection, and relates to the technical field of medicine manufacturing. The main medicine of the composition comprises pantoprazole sodium and melatonin, wherein the melatonin comprises a quick release part and a cyclodextrin-included slow release part. According to the pantoprazole sodium composition for injection provided by the invention, the therapeutic effect of the product is improved, instability caused by oral administration of MT (Melatonin) is avoided and MT is quick to distribute and eliminate and the like, and the first pass effect of MT is reduced. The dosage of pantoprazole sodium is reduced, and the side effect of pantoprazole sodium is reduced. The design of dosage combining quick release and slow release is in accordance with secretion characteristic of MT, so that the problem of half-life period of MT is solved and the bioavailability of a product is improved. The composition has the synergistic effect for treating gastric ulcer by pantoprazole sodium, and pantoprazole sodium and melatonin are combined to not only treat gastric ulcer, but also accelerate ulcer healing, so that the therapeutic effect of pantoprazole sodium is improved. The course of treatment is shortened, the use level of pantoprazole sodium is further reduced, the side effect of pantoprazole sodium is reduced, and the immunity of a human body can be improved.
INTRODUCTION: This review summarizes our current understanding of the respiratory microbiome in COPD and Bronchiectasis. We explore the interplay between microbial communities, host immune responses, disease pathology, and treatment outcomes.
AREAS COVERED: We detail the dynamics of the airway microbiome, its influence on chronic respiratory diseases, and analytical challenges. Relevant articles from PubMed and Medline (January 2010-March 2024) were retrieved and summarized. We examine clinical correlations of the microbiome in COPD and bronchiectasis, assessing how current therapies impact upon it. The potential of emerging immunotherapies, antiinflammatories and antimicrobial strategies is discussed, with focus on the pivotal role of commensal taxa in maintaining respiratory health and the promising avenue of microbiome remodeling for disease management.
EXPERT OPINION: Given the heterogeneity in microbiome composition and its pivotal role in disease development and progression, a shift toward microbiome-directed therapeutics is appealing. This transition, from traditional 'pathogencentric' diagnostic and treatment modalities to those acknowledging the microbiome, can be enabled by evolving crossdisciplinary platforms which have the potential to accelerate microbiome-based interventions into routine clinical practice. Bridging the gap between comprehensive microbiome analysis and clinical application, however, remains challenging, necessitating continued innovation in research, diagnostics, trials, and therapeutic development pipelines.
Patients receive venetoclax orally PO QD on days 1-14. Patients also receive ASTX727 PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: The oral gonadotropin-releasing hormone antagonist relugolix, which temporarily stops menstruation, is used to treat heavy menstrual bleeding, pelvic pressure, and low back pain in women with uterine fibroids. Treatment can also help women recover from low hemoglobin levels and possibly shrink the fibroids. However, evidence of preoperative use of relugolix before laparoscopic myomectomy is limited. Nevertheless, the treatment could reduce interoperative blood loss, decrease the risk of developing postoperative anemia, and shorten the operative time. Thus, we aim to test whether 12-week preoperative treatment with relugolix (40 mg orally, once daily) is similar to or not worse than leuprorelin (one injection every 4 weeks) to reduce intraoperative blood loss.
METHODS: Efficacy and safety of preoperative administration of drugs will be studied in a multi-center, randomized, open-label, parallel-group, noninferiority trial enrolling premenopausal women ≥ 20 years of age, diagnosed with uterine fibroids and scheduled for laparoscopic myomectomy. Participants (n = 80) will be recruited in the clinical setting of participating institutions. The minimization method (predefined factors: presence or absence of fibroids ≥ 9 cm and the International Federation of Gynecology and Obstetrics [FIGO] type 1-5 fibroids) with randomization is used in a 1:1 allocation. Relugolix is a 40-mg oral tablet taken once a day before a meal, for 12 weeks, up to the day before surgery. Leuprorelin is a 1.88 mg, or 3.75 mg subcutaneous injection, given in three 4-week intervals during patient visits before the surgery. For the primary outcome measure of intraoperative bleeding, the blood flow is collected from the body cavity, surgical sponges, and collection bag and measured in milliliters. Secondary outcome measures are hemoglobin levels, myoma size, other surgical outcomes, and quality-of-life questionnaire responses (Kupperman Konenki Shogai Index and Uterine Fibroid Symptoms-Quality of Life).
DISCUSSION: Real-world evidence will be collected in a clinical setting to use pre-treatment with an oral gonadotropin-releasing hormone antagonist to reduce intraoperative bleeding in women who undergo laparoscopic myomectomy.
TRIAL REGISTRATION: jRCTs031210564 was registered on 19 January 2022 in the Japan Registry of Clinical Trials ( https://jrct.niph.go.jp ).
Coronary heart disease (CHD) is caused by a narrowing of the small blood vessels that supply blood and oxygen to the heart. It is the leading cause of death in the United States. Recent evidence has suggested that depression is a significant risk factor for individuals with CHD and may place additional strain on the heart. Selective serotonin reuptake inhibitors (SSRIs), a type of antidepressant medication, have been shown to be especially effective at reducing depression symptoms, particularly for individuals with CHD. However, many people fail to benefit from medication alone or they experience negative side effects. Therefore, a need exists to identify alternative approaches for treating depression in individuals with CHD. Preliminary research has shown that exercise may be an effective way to improve mood and treat depression. More research, however, is needed to confirm the benefits of exercise in individuals with CHD. The purpose of this study is to compare the effectiveness of a supervised exercise program, antidepressant treatment, and placebo in reducing depression and improving heart function in individuals with CHD.

This 16-week study will enroll adults with a history of CHD and depression. Participants will be randomly assigned to an aerobic exercise program, antidepressant medication, or placebo. At study entry, standardized psychological questionnaires will be completed and depression levels and exercise tolerance will be assessed. Participants' heart function will be evaluated through measures of flow-mediated vasodilatation, inflammation, platelet function, baroreflex, and heart rate variability. Participants assigned to the exercise program will be required to engage in structured aerobic exercise. Participants assigned to antidepressant medication will receive sertraline, an SSRI or placebo. The treating psychiatrist will be blinded to pill condition and will use supportive measures to help manage medication side effects. Outcome assessors will be unaware of patients' treatment assignments, and only the research pharmacist will be aware of which patients are assigned to sertraline or to placebo.

At Week 16, participants will return to the clinic for repeat assessments of baseline measures. A follow-up evaluation will occur six months following the end of treatment, and participants' depression levels and clinical status will be assessed.
MYHIBBIN should not be used without the supervision of a physician with experience in immunosuppressive therapy.

MYHIBBIN should not be used interchangeably with mycophenolic acid delayed-release tablets without supervision of a physician with experience in immunosuppressive therapybecause the rates of absorption following the administration of MYHIBBIN and mycophenolic acid delayed-release tablets are not equivalent. 

Patients should avoid contact of the skin or mucous membranes with MYHIBBIN. If such contact occurs, they must wash the area of contact thoroughly with soap and water. In case of ocular contact, rinse eyes with plain water.

The initial oral dose of MYHIBBIN should be given as soon as possible following kidney, heart or liver transplant. It is recommended that MYHIBBIN be administered on an empty stomach. In stable transplant patients, however, MYHIBBIN may be administered with food if necessary [see Clinical Pharmacology (12.3)]. MYHIBBIN must not be mixed with any liquids prior to dose administration. If needed, MYHIBBIN can be administered via a nasogastric tube with a minimum size of 8 French (minimum 1.7 mm interior diameter). 

Patients should be instructed to take a missed dose as soon as they remember, except if it is closer than 2 hours to the next scheduled dose; in this case, they should continue to take MYHIBBIN at the usual times.
The invention relates to an ephedra root supercritical CO2 extract as well as a preparation method and antiperspirant application thereof, and belongs to the field of pharmaceutical technology. The antiperspirant is prepared from an ephedraceae plant, namely ephedra sinica, by virtue of a supercritical CO2 extraction method. The ephedra root supercritical CO2 extract is prepared by the following steps: firstly, crushing ephedra root into the coarsest powder; then, adding the crushed coarse powder into a multi-layer charging barrel and an extraction kettle, and adding ethanol; and finally, eluting a residual solvent through supercritical CO2, so that the ephedra root supercritical CO2 extract is obtained. The technology has the characteristics that through reverse extraction of the material in the multi-layer charging barrel, the technology is uniform in pressure distribution, rapid in mass transfer and high in efficiency; and CO2 is human-friendly and environment-friendly, and the technology is simple in process, high in product purity and yield, significant in energy-saving and efficiency-improving and suitable for industrial production. The invention has the beneficial effects that the technology fills the blank of preparing the ephedra root supercritical CO2 extract, and the antiperspirant activity is proved at home and abroad for the first time. The obtained antiperspirant is pure natural, mild in property, low in irritation to skin and good in environmental protection property.
PURPOSE: A fusion protein with the increased in vivo activity of erythropoietin (EPO) is provided to significantly increase the in vivo half life of the EPO by way of the large amount of amino acids. CONSTITUTION: A fusion protein has a structure where the carboxy terminal peptide (CTP) of thrombopoietin (TPO) is fused to the carboxy terminal of the EPO. The CTP contains the amino acids placed at the 176th to 353rd loci of the TPO presented at the sequence No. 1, or the amino acids placed at the 337th to 353rd loci of the TPO presented at the sequence No. 2. A nucleic acid codes the fusion protein, and a recombinant vector contains the nucleic acid. A chinese hamster ovary (CHO) transformed into the recombinant vector with the nucleic acid is cultured to prepare a fusion protein where the in vivo activity of EPO is increased.
The present invention relates to a channel warming and collateral dredging medicine wine. In the prior art, the Chinese medical science and the Western drugs for treating angiitis mostly provide effects of heat clearing and detoxification, such that the Chinese medical science and the Western medicine for treating the angiitis can not provide therapeutical effects for angiitis patients caused by yang deficiency and qi deficiency. A purpose of the present invention is to provide main therapeutical effects of channel warming and collateral dredging for the patient group in the prior art, such that the treatment characteristics of short treatment period and no recurrence are really realized. For thromboangiitis obliterans patients with qi deficiency, blood deficiency, cold limbs or blood stasis, particular acral blood stasis, 20 ml of the medicine wine is respectively taken on the morning and at the evening, and a course of the medicine wine comprises 30 days. The medicine wine adopts clinical characteristics, pathological changes and hemorheology changes of thrombophlebitis as the aims. The thrombophlebitis belongs to the scope of blood stasis, has characteristics of yang deficiency, qi deficiency blood stasis, body chilly, particularly acral chilly at early stage, and mainly has characteristics of thermal imagery at advanced stage due to long-time blood stasis. Therefore, if the channel warming and collateral dredging medicine wine provided by the present invention can be taken in time at the early stage of the disease, the yangqi can be restored, the qi and the blood can be smooth, the meridians can be dredged, the congestion can be dissipated, such that the microcirculation blood flow can be promoted, the blood cell aggregation can be reduced, the capillary network opening is improved so as to improve the abnormal hemorheology and the blood flow status, and help to restore the vascular intima lesions.
The present invention relates to personal cleansing wipe articles which have superior softness, feel and cleansing properties. The wipes of the present invention comprise a substrate and an aqueous liquid cleansing composition which is coated onto or impregnated into said substrate to the extent of from about 100 % to about 400 % by weight of the substrate. The substrate is a single-layer, nonwoven substrate which is formed from hydroentangled fibers. Upon a substantial portion of a base surface comprising the substrate there exists a three-dimensional pattern comprising a plurality of discrete, raised fibrous regions. The raised fibrous regions have a density which is substantially the same as the density of the base surface. The raised fibrous regions are joined to the base surface by a fibrous transition region. The aqueous liquid cleansing composition comprises an effective amount of a cleansing surfactant.
PEGISUS is based on two existing evidence-based interventions: Reducing Alcohol and Drug use and other Problem behavior in Adolescent Learners (RAD-PAL) and Manhood 2.0. RAD-PAL was developed to target primary substance use and other challenging behaviors. Manhood 2.0 was developed to reduce traditional gender beliefs. These interventions have been adapted based on formative work with the target user group. PEGISUS will be embedded into existing vocational training programs and delivered by existing staff at these institutions.
Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle.
The present provides a carrier molecule for transporting a polyanioic macromolecule such as a nucleic acid across a biological barrier of a cell. The carrier has a biocompatible backbone polymer with two or more polycationic polymer fragments covalently linked. In one embodiment, the backbone polymer is polyethylene glycol (PEG) and the polycationic polymer is polyethylenimine (PEI). The copolymer carrier molecule can be complexed with a polyanionic macromolecule such as a nucleic acid (NA). The NA/copolymer complex is stable in biological conditions by forming a special coreshell-like micelle structure. The nucleic acid can be rapidly released from the complex when biodegradation linker are used to bind the polycationic polymer fragments to the polymer backbone. The carriers and complexes of the invention can be used tin methods of delivering the polycainonic macromolecules to cells both in vitro and in vivo.
As skin ages, intrinsic and extrinsic factors contribute to cellular senescence, disrupting the skin's structure and function. Senescent cells accumulate in the skin, leading to the secretion of senescence-associated secretory phenotype (SASP) factors, which promote inflammation and degrade extracellular matrix proteins like collagen. These changes result in wrinkles, loss of elasticity, and reduced skin barrier function. The study explores anti-senescence strategies using senolytic agents that selectively eliminate senescent cells, aiming to rejuvenate the skin. Compounds like PCC1 and Cellumiva have shown promise in targeting senescent cells by inducing apoptosis and reducing SASP expression, offering a novel approach to skin aging therapy.

This clinical trial is designed to evaluate the efficacy and safety of PCC1 and the senolytic complex Cellumiva in skin rejuvenation over 12 weeks. Healthy female participants aged 45-65 will be randomly assigned to receive PCC1, Cellumiva (a blend including procyanidin C1, Pterostilbene, and Spermidine), or a placebo. The study will measure skin barrier function, wrinkle reduction, and texture/radiance improvements using imaging technologies and participant feedback. Safety will also be monitored through adverse event reporting.
Participants (n=32) will undergo extended treatment period covering the start, peak and end phases of smog episodes in Beijing, with either true or sham air cleaner treatment and then alternate the treatment after a wash out interval (Air cleaner use method 2). Exposure monitoring for PM2.5 will continue throughout the treatment period and repeated health examinations will be conducted at time points corresponding to the start, peak and end phases of the smog episodes.
Cerebral palsy (CP) is a common neurodevelopmental disorder characterized by pronounced motor dysfunction and resulting in physical disability. Neural precursor cells (NPCs) have shown therapeutic promise in mouse models of hypoxic-ischemic (HI) perinatal brain injury, which mirror hemiplegic CP. Constraint-induced movement therapy (CIMT) enhances the functional use of the impaired limb and has emerged as a beneficial intervention for hemiplegic CP. However, the precise mechanisms and optimal application of CIMT remain poorly understood. The potential synergy between a regenerative approach using NPCs and a rehabilitation strategy using CIMT has not been explored. We employed the Rice-Vannucci HI model on C57Bl/6 mice at postnatal day (PND) 7, effectively replicating the clinical and neuroanatomical characteristics of hemiplegic CP. NPCs were transplanted in the corpus callosum (CC) at PND21, which is the age corresponding to a 2-year-old child from a developmental perspective and until which CP is often not formally diagnosed, followed or not by Botulinum toxin injections in the unaffected forelimb muscles at PND23, 26, 29 and 32 to apply CIMT. Both interventions led to enhanced CC myelination and significant functional recovery (as shown by rearing and gait analysis testing), through the recruitment of endogenous oligodendrocytes. The combinatorial treatment indicated a synergistic effect, as shown by newly recruited oligodendrocytes and functional recovery. This work demonstrates the mechanistic effects of CIMT and NPC transplantation and advocates for their combined therapeutic potential in addressing hemiplegic CP.
BACKGROUND: The aim of this study was to evaluate the use of machine learning to predict persistent opioid use after hand surgery.
METHODS: The authors trained 2 algorithms to predict persistent opioid use, first using a general surgery data set and then using a hand surgery data set, resulting in 4 trained models. Next, the authors tested each model's performance using hand surgery data. Participants included adult surgery patients enrolled in a cohort study at an academic center from 2015 to 2018. The first algorithm (Michigan Genomics Initiative model) was designed to accommodate patient-reported data and patients with or without prior opioid use. The second algorithm (claims model) was designed for insurance claims data from patients who were opioid-naive only. The main outcome was model discrimination, measured by area under the receiver operating curve (AUC).
RESULTS: Of 889 hand surgery patients, 49% were opioid-naive and 21% developed persistent opioid use. Most patients underwent soft-tissue procedures (55%) or fracture repair (20%). The Michigan Genomics Initiative model had AUCs of 0.84 when trained only on hand surgery data, and 0.85 when trained on the full cohort of surgery patients. The claims model had AUCs of 0.69 when trained only on hand surgery data, and 0.52 when trained on the opioid-naive cohort of surgery patients.
CONCLUSIONS: Opioid use is common after hand surgery. Machine learning has the potential to facilitate identification of patients who are at risk for prolonged opioid use, which can promote early interventions to prevent addiction.